Short Interest in Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Rises By 20.0%

Dermata Therapeutics, Inc. (NASDAQ:DRMAWGet Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 12,600 shares, a growth of 20.0% from the February 29th total of 10,500 shares. Based on an average daily volume of 5,700 shares, the days-to-cover ratio is currently 2.2 days.

Dermata Therapeutics Stock Performance

NASDAQ:DRMAW opened at $0.01 on Friday. The company has a fifty day moving average of $0.02 and a 200 day moving average of $0.02. Dermata Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.07.

About Dermata Therapeutics

(Get Free Report)

Dermata Therapeutics, Inc, a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

See Also

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.